Welcome to the

Molecular Tumor Profiling

(Foundation One®CDx Service, Next-Generation Sequencing)

FoundationOneCDx_Logo.png
FoundationOne®CDx provides a comprehensive molecular tumour profile for solid tumors which can support doctors in their decisions regarding the treatment of cancer patients by detecting genetic changes associated with cancer.
• Validated NGS-based analysis of the four main classes of genomic alterations.1
• Complete Sequencing of the exons of 324  genes and additional introns from 36 selected genes.
( FoundationOne®CDx Gene Panel)
• Measurement of the Tumor Mutational Burden (TMB) und the Microsatellite Instability (MSI-Status) is included in the analysis.2

Comprehensive approach gives relieable results
• FoundationOne®CDx recognizes all genetic alterations – base substitutions, insertions/deletions, copy number variations and gene rekombinations (fusions).
• FoundationOne®CDx is a comprehensive tumor profiling, which is based on a largevalidation study. The study was published in a leading scientific journal.1

Saves tissue and time
• FoundationOne®CDx needs only a small amount of tissue, including routine biopsies and fine needle aspirates.
• The test works optimal with a tumor content of 30%, the minimum is 20%.

Applicable results summarized in a report
• All determined clinical relevant genetic alterations will be analyzed on basis of the current scientific knowledge and clinical data with personalized therapies and clinical trial data.
• more than 20 bioinformaticians and biomedical scientists curate the FoundationOne®CDx report according to the latest available information.
FoundationOne® CDx Report - Example

1 Frampton GM et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31(11):1023–1031.
2 Chalmers ZR et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 2017;9(1):34.

Order Form FoundationOne®CDx Service
Order Form 

Further Information to the Order
Order Instructions
Specimen Instructions

Information 
Molecular Tumor Profiling
Dr. rer. nat. Martin Zoche
Phone +41 43 253 03 34
Mobile +41 79 788 91 57
martin.zoche@usz.ch

Collaboration Partners
As licensee of the Foundation Medicine® Services outside of the US, Roche has sublicensed the provision of these services in Switzerland to the UniversitätsSpital Zürich.

Roche.png 
Hoffmann La Roche AG, Basel, Switzerland
 
FoundationOneInc.png
Foundation Medicine® Inc,, Cambridge, USA

usz.png
University Hospital Zurich, Switzerland

To top of page

We use cookies to make our website user-friendly, to continuously improve it and to analyze the traffic of our website. By continuing to browse the site, you are agreeing to our use of cookies. Further information can be found in our privacy policy.